Tiziana's INFORM-MS Phase 2a Hits Both Primary Endpoints in na-SPMS
TLSA sits 17% above its 52-week low of $0.762.
Summary
Tiziana's Phase 2a INFORM-MS trial of intranasal foralumab met both primary endpoints in non-active secondary progressive MS — a significant PET imaging reduction in microglial activation at the 50 ug dose (p=0.0168) plus clean safety — and showed clinically meaningful fatigue improvement in both dose arms.
Key Events · Product Development and Regulatory · TLSA
-
INFORM-MS Meets Both Primary Endpoints
The Phase 2a trial hit its neuroinflammation endpoint with a statistically significant reduction in microglial activation on TSPO PET for the 50 ug arm versus placebo (p=0.0168) and met its safety/tolerability objective.
-
Fatigue Scores Improve Clinically
MFIS total score fell -6.17 points at 50 ug (p=0.035) and -7.18 at 100 ug (p=0.040) versus -3.12 for placebo, exceeding the 4-point clinically significant threshold, though the trial was not powered for clinical endpoints.
-
Clean Safety Across 48 Patients
All 48 participants completed treatment with no deaths, no discontinuations due to adverse events and no study-drug related serious adverse events; treatment-emergent events occurred in 76.7% of foralumab patients versus 83.3% of placebo.
-
100 ug Arm Misses PET Endpoint
No statistically significant PET difference was seen in the 100 ug arm (n=11), and the EDSS disability secondary endpoint showed no change over the 3-month treatment period.
Analysis · TLSA · Life Sciences
This is the first hard efficacy data for intranasal foralumab in non-active secondary progressive MS, a disease with no FDA-approved therapy. At the 50 ug dose, the trial produced a statistically significant reduction in microglial activation on TSPO PET versus placebo (p=0.0168), and both doses were safe and well tolerated, with no discontinuations or drug-related serious adverse events across 48 patients. Fatigue, a hallmark of the disease, improved by more than 4 points on the MFIS in both treatment arms — a clinically meaningful threshold — though the study was not powered for clinical endpoints and the EDSS disability measure did not move over 3 months. For a clinical-stage company that reported a $12.4M first-half loss with only $3.9M of cash and going-concern doubt on 2026-10-16, a clean win on the primary endpoint is the difference between a fundable pipeline and a financing crunch; the next gate is an FDA discussion on the path forward, with full data to be presented at a scientific congress.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.6M. The 52-week trading range was $0.76 to $1.96. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.